Dergiler / Uluslararası Hematoloji-Onkoloji Dergisi / 2019 / Cilt: 29 - Sayı: 3

CD25 Expression is Associated with Autoimmunity in Patients with CLL

KLL’li Hastalarda CD25 Ekspresyonu Otoimmünite ile İlişkilidir

Sayfa
123–129
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Since this study is the first to demonstrate the relationship between CD25 expression and autoimmune cytopenia in patients with CLL, it may be of guidance for future studies on the same subject and may draw the attention of clinicians to this in clinical practice.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:t has been shown that CD25 is expressed more in Chronic Lymphocytic Leukemia (CLL) cases.
📊
Temel Bulgular & Veri:The aim of this study was to examine the prognostic significance of CD25 in cases in our centre.
💡
Sonuç & Katkı:Since this study is the first to demonstrate the relationship between CD25 expression and autoimmune cytopenia in patients with CLL, it may be of guidance for future studies on the same subject and may draw the attention of clinicians to this in clinical practice.
🔬Tür:Araştırma Makalesi
📍Kapsam:2009 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

t has been shown that CD25 is expressed more in Chronic Lymphocytic Leukemia (CLL) cases. However, there is conflicting data as to its prognostic significance. The aim of this study was to examine the prognostic significance of CD25 in cases in our centre. A retrospective examination was made of hospital records and flow cytometry results at the time of diagnosis of 160 patients diagnosed with CLL in our clinic between June 2009 and April 2018. An analysis of cases with and without CD25 cell surface expression for overall survival and time to treatment revealed no significant difference between the two groups in respect of both parameters (Graphic 1, p> 0.05 and Graphic 2, p> 0.05). Autoimmune cytopenia was determined to be significantly more common in the CD25-negative group. CD25 was seen to have no prognostic significance in CLL. However, a significantly increased rate of autoimmune cytopenia was determined in cases with CD25 negativity. Since this study is the first to demonstrate the relationship between CD25 expression and autoimmune cytopenia in patients with CLL, it may be of guidance for future studies on the same subject and may draw the attention of clinicians to this in clinical practice.

Abstract

CD25’in KLL (Kronik Lenfositik Lösemi) vakalarında daha fazla eksprese edildiği gösterilmiştir. Ancak prognostik bir öneminin olup olmadığı ile ilgili çelişkili çalışmalar mevcuttur. Biz de kendi vakalarımızda CD25’in prognostik önemine bakmak istedik. Haziran 2009 ve Nisan 2018 tarihleri arasında kliniğimizde KLL tanısı almış 160 hastanın retrospektif olarak hastane kayıtları ve tanı anındaki akım sitometri sonuçları incelendi. CD25 hücre yüzeyi ekspresyonu olan ve olmayan olgular, overall survival ve time to treatment için değerlendirildiğinde her ikisi içinde iki grup arasında istatistiksel olarak anlamlı düzeyde fark olmadığı tespit edilmiştir (Grafik 1, p> 0.05 ve Grafik 2, p> 0.05). Ancak CD25 negatif olan grupta otoimminositopeni, istatistiksel olarak daha fazla görüldü. CD25’in KLL’de prognostik bir önemi olmadığını gösterdik. Ancak CD25 negatifliği ile otoimmunsitopenilerin sıklığının istatistiksel olarak arttığını gördük. Çalışmamız CD25 ekspresyonunun KLL hastalarında otoimminositopeni ile ilişkisini gösteren ilk çalışma olduğu için bundan sonra yapılacak olan çalışmalara ışık tutabilir ve klinisyenlerin klinik pratikte bu konuya dikkatlerini çekebilir.

🔖

Bu Makaleye Atıf Yap

ÖZTÜRK, H. B. A., YILDIZ, A., ALBAYRAK, M., PALA, Ç., MARAL, S., YILMAZ, M. F. (2019). CD25 Expression is Associated with Autoimmunity in Patients with CLL. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 29 - Sayı: 3, 123–129. https://ajindex.com/articles/322754

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990-4997, 1996
  2. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 333: 1052-1057, 1995. Review. Erratum in: N Engl J Med 333: 1515, 1995
  3. Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456, 2008. Erratum in: Blood 112: 5259, 2008
  4. Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica 96: 752-761, 2011
  5. Visco C, Rodeghiero F. Immune thrombocytopenia in lymphoproliferative disorders. Hematol Oncol Clin North Am 23: 1261-1274, 2009
  6. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 23: 47-59, 2010
  7. Zent CS, Ding W, Reinalda MS, et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma 50: 1261-1268, 2009
  8. Shvidel L, Braester A, Bairey O, et al; Israeli CLL Study Group. Cell surface expression of CD25 antigen (surface IL-2 receptor α-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients. Ann Hematol 91: 1597-602, 2012
  9. Tefferi A, Bartholmai BJ, Witzig TE, et al. Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 95: 173-177, 1997
  10. Nakase K, Kita K, Miwa H, et al. Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis. Leukemia 21: 326-332, 2007
  11. Oki Y, Kato H, Matsuo K, et al. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma 49: 1345-1351, 2008
  12. Hjalmar V, Hast R, Kimby E. Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical c